Advanced Biomed Inc. Common Stock (ADVB) Debt/Equity Ratio: History & Chart

Advanced Biomed Inc. Common Stock(ADVB)

Medical - Diagnostics & Research · New York City, NY

$6.57+0.23 (+3.63%)

Delayed quote: Oct 6, 2026, 11:04 AM EDT

About Advanced Biomed Inc. Common Stock

Advanced Biomed Inc. functions as an investment holding company, primarily dedicated to the research and development of microfluidic biochip technologies. Based in Taiwan, the company leverages these innovations to enhance precision oncology, spanning cancer detection, diagnosis, and treatment. Its diverse product portfolio includes a suite of advanced devices: A+Pre: A fully automated system designed for pre-concentrating diluted blood samples. AC-1000: A rare cell device engineered to address the challenges of detecting cells in hypercoagulable samples from tumor patients. A+SCDrop: A specialized tool for capturing individual circulating tumor cells (CTCs). A+CellScan: An analyzer featuring an immunostaining chip, utilized for the immunostaining and analysis of output from the AC-1000. Beyond standalone devices, Advanced Biomed provides microfluidic biochips, including the A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips, which are integral to delivering assay products and services to cancer patients. The company also offers a comprehensive range of immunochromogenic kits: A+CTCE kit: Used to identify epithelial circulating tumor cells by detecting EpCAM, CK (pan), CD45, and CD14 antibodies. A+CTCM kit: Targets mesenchymal circulating tumor cells through their expression of Vimentin, CD45, and CD14 antibodies. A+EMT kit: Designed for the identification of epithelial-to-mesenchymal circulating tumor cells, focusing on cell-surface Vimentin, CD45, and CD14 antibodies. A+CM kit: Facilitates the detection of tumor-associated macrophages by assessing PD-L1, CD45, and CD14 antibodies. In addition to its current offerings, Advanced Biomed is actively developing A+LCGuard, a promising solution for the early screening of lung cancer. The company further expands its presence by establishing and operating medical clinics in the People's Republic of China. Founded in 2014, Advanced Biomed Inc. maintains its corporate headquarters in New York, New York.

New York City, NY

31 employees

www.advanbiomed.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Xiaomin Chen

View full financials

ADVB Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.08

DEBT TO EQUITY RATIO AVG TTM

0.23

DEBT TO EQUITY RATIO AVG 3Y

0.31

DEBT TO EQUITY RATIO AVG 5Y

N/A

DEBT TO EQUITY RATIO AVG 10Y

N/A

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-65.77%

CURRENT VS 3Y AVG

-74.89%

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.13

median of 576 covered companies

CURRENT VS SECTOR MEDIAN

-40.49%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Advanced Biomed Inc. Common Stock (ADVB)	$9.08M	0.08	0.23	0.31	N/A
SeaStar Medical Holding Corporation (ICU)vs ›	$8.97M	0.00	0.05	0.05	0.05
Jasper Therapeutics, Inc. (JSPR)vs ›	$9.35M	0.19	0.16	0.12	0.10
Healthcare Triangle, Inc. (HCTI)vs ›	$8.48M	0.26	1.08	0.76	0.48
Ainos, Inc. (AIMD)vs ›	$9.72M	4.21	1.11	0.63	0.57
HeartSciences Inc. (HSCS)vs ›	$8.31M	N/A	16.01	9.73	9.73
DataMEDS AI, Inc. (MEDS)vs ›	$8.31M	N/A	3.73	3.73	3.73
Medicus Pharma Ltd. Common Stock (MDCX)vs ›	$10.04M	N/A	0.05	0.05	0.05
Aprea Therapeutics, Inc. (APRE)vs ›	$8.12M	0.00	0.00	0.00	0.00
MetaVia Inc. (MTVA)vs ›	$10.08M	0.03	0.03	0.02	0.01

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Advanced Biomed Inc. Common Stock (ADVB)

$9.08M

0.08

0.23

0.31

N/A

SeaStar Medical Holding Corporation (ICU)vs ›

$8.97M

0.00

0.05

Jasper Therapeutics, Inc. (JSPR)vs ›

$9.35M

0.19

0.16

0.12

0.10

Healthcare Triangle, Inc. (HCTI)vs ›

$8.48M

0.26

1.08

0.76

0.48

Ainos, Inc. (AIMD)vs ›

$9.72M

4.21

1.11

0.63

0.57

HeartSciences Inc. (HSCS)vs ›

$8.31M

N/A

16.01

9.73

DataMEDS AI, Inc. (MEDS)vs ›

$8.31M

N/A

3.73

Medicus Pharma Ltd. Common Stock (MDCX)vs ›

$10.04M

N/A

0.05

Aprea Therapeutics, Inc. (APRE)vs ›

$8.12M

0.00

MetaVia Inc. (MTVA)vs ›

$10.08M

0.03

0.02

0.01

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Advanced Biomed Inc. Common Stock (ADVB)?

The debt to equity ratio for ADVB stock is 0.08.

Is Advanced Biomed Inc. Common Stock's debt to equity ratio high or low?

The debt to equity ratio of 0.08 is 59% below its 4-year average of 0.19, near the low end of its 4-year range (0.00–3.09).

What is the TTM average debt to equity ratio for Advanced Biomed Inc. Common Stock (ADVB)?

The TTM average debt to equity ratio for ADVB stock is 0.23.

What is the 3Y average debt to equity ratio for Advanced Biomed Inc. Common Stock (ADVB)?

The 3Y average debt to equity ratio for ADVB stock is 0.31.

DATE	DEBT TO EQUITY RATIO
2026-03-31	0.08
2025-12-31	0.08
2025-09-30	0.57
2025-06-30	0.36
2025-03-31	0.05
2024-12-31	3.09
2024-09-30	1.21
2024-06-30	0.08
2024-03-31	0.08
2023-12-31	0.66
2023-09-30	0.23
2023-06-30	0.19
2023-03-31	0.13
2022-12-31	0.00
2022-09-30	0.00
2022-06-30	0.13

DATE

DEBT TO EQUITY RATIO

2026-03-31

0.08

2025-12-31

0.08

2025-09-30

0.57

2025-06-30

0.36

2025-03-31

0.05

2024-12-31

3.09

2024-09-30

1.21

2024-06-30

0.08

2024-03-31

0.08

2023-12-31

0.66

2023-09-30

0.23

2023-06-30

0.19

2023-03-31

0.13

2022-12-31

0.00

2022-09-30

0.00

2022-06-30

0.13

Debt to Equity Ratio: 0.08

ADVB Debt to Equity Ratio

ADVB Average Debt to Equity Ratio Chart

ADVB Current vs Average Debt to Equity Ratio Chart

ADVB Debt to Equity Ratio Metrics

ADVB Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

ADVB Debt to Equity Ratio History

Related Metrics